Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome

OBJECTIVE: To explore whether gene expression profiling can identify a molecular mechanism for the clinical benefit of canakinumab treatment in patents with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Blood samples were collected from 20 patients with active TRAPS...

Descripción completa

Detalles Bibliográficos
Autores principales: Torene, Rebecca, Nirmala, Nanguneri, Obici, Laura, Cattalini, Marco, Tormey, Vincent, Caorsi, Roberta, Starck-Schwertz, Sandrine, Letzkus, Martin, Hartmann, Nicole, Abrams, Ken, Lachmann, Helen, Gattorno, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264306/
https://www.ncbi.nlm.nih.gov/pubmed/27474763
http://dx.doi.org/10.1136/annrheumdis-2016-209335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264306/
https://www.ncbi.nlm.nih.gov/pubmed/27474763
http://dx.doi.org/10.1136/annrheumdis-2016-209335

Ejemplares similares